Related Experiment Video
Updated: May 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events
Nina Djukanovic1, Zoran Todorovic, Slobodan Obradovic
1Department of Cardiology, Institute for Cardiovascular Diseases, Clinical Centre of Serbia, Serbia.
Insights
Discontinuing one year of clopidogrel therapy after coronary stent implantation showed a low rate of thrombotic events. Platelet aggregation increased with adenosine diphosphate and arachidonic acid, but not thrombin receptor activating peptide.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Dual antiplatelet therapy with aspirin and clopidogrel is standard after coronary stent implantation.
- The optimal duration of clopidogrel therapy and the risks of its discontinuation require further investigation.
Purpose of the Study:
- To evaluate the incidence of thrombotic events after one year of clopidogrel discontinuation in patients with coronary stents.
- To assess changes in platelet aggregability following clopidogrel cessation.
Main Methods:
- Prospective, multicenter study of 200 patients treated with aspirin + clopidogrel for one year post-stent.
- Platelet aggregation measured using adenosine diphosphate with PGE(1) (ADPHS), arachidonic acid (ASPI), and thrombin receptor activating peptide (TRAP) at baseline and 10, 45, 90 days post-cessation.
- Six-month follow-up for thrombotic events.
Main Results:
- A low incidence of thrombotic events (1%) was observed, including one ischemic stroke and one myocardial infarction.
- Platelet aggregation induced by ADPHS and ASPI significantly increased 10-90 days after clopidogrel cessation (P < 0.001).
- TRAP-induced platelet aggregation remained unchanged throughout the study period.
Conclusions:
- The risk of thrombotic events after one year of clopidogrel discontinuation in patients with coronary stents may be lower than anticipated.
- While platelet reactivity to certain agonists increases post-cessation, this may not translate to a high thrombotic event rate.
Abstract:
We aimed to examine the rate of thrombotic events after discontinuation of one year clopidogrel therapy in patients with implanted coronary stent, and to determine platelet aggregability by multiple electrode analyzer after cessation of clopidogrel. This prospective, multicenter study enrolled 200 patients subjected to coronary stent implantation and treated with aspirin + clopidogrel one year after the stent placement. Platelet aggregation was measured using 3 agonists [adenosine diphosphate with PGE(1) (ADPHS), arachidonic-acid (ASPI), and thrombin receptor activating peptide (TRAP)] on the day of cessation of clopidogrel and at 10, 45, and 90 days after clopidogrel was stopped. Two thrombotic events were registered during the 6-months follow up (one ischemic stroke and one myocardial infarction; incidence of 1%). The mean values of ADP + PGE(1)- and ASPI-induced aggregation 10 - 90 days after the cessation of clopidogrel were significantly higher than values obtained before the termination of the drug (P < 0.001, all). Cessation of clopidogrel did not influence the TRAP-induced aggregation, which reached the plateau in all measurements. In conclusion, the incidence of thrombotic events after the cessation of one-year clopidogrel treatment might be lower than expected in patients with implanted coronary stent.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care